Enlivex Registers 23.3M Shares for Resale by Noteholder, Creating Potential Market Overhang
ENLV sits 36% above its 52-week low of $0.66.
Summary
Enlivex has filed an F-3 registration statement for the resale of 23.3 million ordinary shares by a selling shareholder, representing potential dilution of nearly 10% of outstanding shares.
Key Events · Financing and Capital Events · ENLV
-
Resale Registration Filed
Enlivex has filed an F-3 registration statement for the resale of up to 23,333,333 ordinary shares by Lind Global Asset Management XIV, LLC.
-
Shares from Convertible Note
These shares are issuable upon conversion of a Senior Secured Convertible Promissory Note, with an aggregate principal amount of $21.0 million, that was issued to the Selling Shareholder on March 23, 2026.
-
No Proceeds to Company
The company will not receive any proceeds from the sale of these ordinary shares; all net proceeds will go to the Selling Shareholder.
-
Significant Potential Dilution
The 23,333,333 shares registered for resale represent approximately 9.68% of the 241,048,724 ordinary shares outstanding as of April 17, 2026, creating a substantial potential market overhang.
Analysis · ENLV · Life Sciences
This F-3 filing registers 23,333,333 ordinary shares for resale by Lind Global Asset Management XIV, LLC, the holder of a Senior Secured Convertible Promissory Note issued on March 23, 2026. While the original debt financing was previously disclosed, this registration formalizes the mechanism for the noteholder to convert and sell shares, creating a significant potential overhang on the stock. The company will not receive any proceeds from these sales. The potential dilution from these shares represents approximately 9.68% of the company's currently outstanding shares, which is a substantial amount and could lead to selling pressure.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $208.5M. The 52-week trading range was $0.66 to $2.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.